Osteogenesis imperfecta

6 trials 3 recruiting MedDRA PT
6 Registered trials
3 Recruiting
4 Unique sponsors
6 Unique IMPs
5 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
M Musculoskeletal (ATC M) 3
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Monoclonal antibody 1 substance
Monoclonal antibody (bone) 1 substance
Phase III: 3 Phase II/III: 1 Phase II: 2

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase III

3 trials
  • Amgen Inc. Commercial
    ROMOSOZUMAB
    2023-503293-21-00 7 countries 2026 n=32
    Recruiting
  • Amgen Inc. Commercial
    ROMOSOZUMAB
    2023-503294-37-00 9 countries 2023 n=51
    Ended
  • Ultragenyx Pharmaceutical Inc. Commercial
    NERIDRONATE SODIUM; PAMIDRONATE DISODIUM; SETRUSUMAB; ZOLEDRONIC ACID
    2023-504196-24-00 5 countries 2023 n=27
    Recruiting

Phase II/III

1 trial
  • Ultragenyx Pharmaceutical Inc. Commercial
    SETRUSUMAB
    2024-510919-29-00 6 countries 2023 n=53 Orphan
    Ended

Phase II

2 trials
  • Angitia Inc. Ltd. Commercial
    HUMANISED IGG4 BISPECIFIC MONOCLONAL ANTIBODY AGAINST SCLEROSTIN AND DICKKOPF-RELATED PROTEIN 1
    2025-522951-24-00 3 countries n=40 Orphan
    Pending
  • Istituto Ortopedico Rizzoli Academic
    IMP not specified
    2024-515516-50-00 1 country 2025 n=15
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Ultragenyx Pharmaceutical Inc. Commercial 2 Phase II/III, Phase III 1
Amgen Inc. Commercial 2 Phase III 1
Angitia Inc. Ltd. Commercial 1 Phase II 0
Istituto Ortopedico Rizzoli Academic 1 Phase II 1
New trials by year
2023
3
2025
1
2026
1
← All indication landscapes